Nicox S.A. 2018 SR
The report outlines Nicox's activities as an international ophthalmology company in 2018, focusing on its proprietary nitric oxide-donating research platform. It highlights key clinical-stage candidates, including NCX 470 for glaucoma and NCX 4251 for blepharitis, alongside FDA-approved products VYZULTA and ZERVIATE. The company details its strategic partnerships with Bausch + Lomb, Eyevance, and Ocumension to optimize global development and commercialization. Additionally, the report describes Nicox's intellectual property portfolio, competitive strengths, and market opportunities within the ophthalmic treatments sector.
Company: Nicox S.A.
Sector: Professional & technical services
Country: France
Year: 2018
Type: SR
Pages: 26
Back to company
Nicox S.A.
Annual Report (Chapter 6 Extract)
The report outlines Nicox's activities as an international ophthalmology company in 2018, focusing on its proprietary nitric oxide-donating research platform. It highlights key clinical-stage candidates, including NCX 470 for glaucoma and NCX 4251 for blepharitis, alongside FDA-approved products VYZULTA and ZERVIATE. The company details its strategic partnerships with Bausch + Lomb, Eyevance, and Ocumension to optimize global development and commercialization. Additionally, the report describes Nicox's intellectual property portfolio, competitive strengths, and market opportunities within the ophthalmic treatments sector.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
2018
Fiscal Year
2018
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees